1. Home
  2. VIRT vs SWTX Comparison

VIRT vs SWTX Comparison

Compare VIRT & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIRT
  • SWTX
  • Stock Information
  • Founded
  • VIRT 2008
  • SWTX 2017
  • Country
  • VIRT United States
  • SWTX United States
  • Employees
  • VIRT N/A
  • SWTX N/A
  • Industry
  • VIRT Investment Bankers/Brokers/Service
  • SWTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VIRT Finance
  • SWTX Health Care
  • Exchange
  • VIRT Nasdaq
  • SWTX Nasdaq
  • Market Cap
  • VIRT 3.3B
  • SWTX 3.5B
  • IPO Year
  • VIRT 2015
  • SWTX 2019
  • Fundamental
  • Price
  • VIRT $40.19
  • SWTX $46.71
  • Analyst Decision
  • VIRT Hold
  • SWTX Buy
  • Analyst Count
  • VIRT 8
  • SWTX 7
  • Target Price
  • VIRT $37.25
  • SWTX $56.86
  • AVG Volume (30 Days)
  • VIRT 898.5K
  • SWTX 4.9M
  • Earning Date
  • VIRT 07-17-2025
  • SWTX 05-09-2025
  • Dividend Yield
  • VIRT 2.39%
  • SWTX N/A
  • EPS Growth
  • VIRT 142.03
  • SWTX N/A
  • EPS
  • VIRT 3.46
  • SWTX N/A
  • Revenue
  • VIRT $2,401,575,000.00
  • SWTX $219,670,000.00
  • Revenue This Year
  • VIRT N/A
  • SWTX $79.29
  • Revenue Next Year
  • VIRT N/A
  • SWTX $70.79
  • P/E Ratio
  • VIRT $11.62
  • SWTX N/A
  • Revenue Growth
  • VIRT 43.16
  • SWTX 730.42
  • 52 Week Low
  • VIRT $21.55
  • SWTX $28.21
  • 52 Week High
  • VIRT $44.58
  • SWTX $62.00
  • Technical
  • Relative Strength Index (RSI)
  • VIRT 47.21
  • SWTX 61.37
  • Support Level
  • VIRT $40.39
  • SWTX $46.21
  • Resistance Level
  • VIRT $41.61
  • SWTX $46.77
  • Average True Range (ATR)
  • VIRT 1.10
  • SWTX 0.15
  • MACD
  • VIRT -0.33
  • SWTX -0.04
  • Stochastic Oscillator
  • VIRT 20.33
  • SWTX 91.67

About VIRT Virtu Financial Inc.

Virtu Financial Inc is a financial firm that leverages cutting edge technology to deliver liquidity to the global markets and innovative, transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

Share on Social Networks: